Published in Hepatology on October 01, 2009
High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology (2010) 4.11
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol (2010) 1.75
Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2012) 1.74
Signals from dying hepatocytes trigger growth of liver progenitors. Gut (2010) 1.67
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr (2011) 1.35
Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol (2014) 1.25
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
The de ritis ratio: the test of time. Clin Biochem Rev (2013) 1.14
Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol (2010) 1.13
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol (2013) 1.07
Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol (2012) 1.07
Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol (2010) 1.07
High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med (2010) 1.05
Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis (2012) 1.05
Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab (2013) 1.04
Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol (2014) 1.04
Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res (2013) 1.03
Toxicant-associated steatohepatitis. Toxicol Pathol (2012) 1.01
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer (2011) 1.00
The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care (2012) 1.00
Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol (2012) 0.98
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One (2011) 0.95
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol (2014) 0.93
Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One (2013) 0.93
Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am (2016) 0.90
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol (2014) 0.89
Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.89
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2014) 0.88
Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y) (2012) 0.87
Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 0.87
Comparative evaluation of differentiation potential of menstrual blood- versus bone marrow-derived stem cells into hepatocyte-like cells. PLoS One (2014) 0.87
Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol (2012) 0.86
Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers. PLoS One (2014) 0.86
Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One (2013) 0.86
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One (2013) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One (2013) 0.85
Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol (2014) 0.84
NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2014) 0.84
Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. J Occup Environ Med (2011) 0.84
Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2014) 0.84
Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol (2009) 0.83
Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology (2013) 0.83
Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol (2015) 0.83
Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl (2010) 0.83
Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat (2011) 0.83
Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques. PLoS One (2012) 0.83
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol (2012) 0.82
Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One (2013) 0.82
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.82
Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data (2015) 0.82
Focus on therapeutic strategies of nonalcoholic Fatty liver disease. Int J Hepatol (2012) 0.82
Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol (2014) 0.81
No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med (2016) 0.81
Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis. Hepatology (2010) 0.81
Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. J Nutr Metab (2011) 0.81
Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer (2015) 0.80
Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol (2015) 0.80
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol (2015) 0.80
ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep (2015) 0.80
γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia (2015) 0.79
Diagnosis of alcoholic liver disease. World J Gastroenterol (2014) 0.79
The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis. Eur J Med Res (2011) 0.79
Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism (2015) 0.79
Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. Clin Transl Gastroenterol (2015) 0.79
One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology (2009) 0.78
Longitudinal effects of MRI-measured hepatic steatosis on biomarkers of glucose homeostasis and hepatic apoptosis in obese youth. Diabetes Care (2012) 0.78
Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One (2015) 0.78
Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. J Pediatr Gastroenterol Nutr (2010) 0.78
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J Gastroenterol (2013) 0.78
Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. Int J Hepatol (2014) 0.78
Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. World J Hepatol (2010) 0.78
Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther (2013) 0.78
Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. PLoS One (2014) 0.78
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci (2016) 0.78
Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci (2015) 0.77
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol (2016) 0.77
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int (2016) 0.77
MR Elastography of Liver Disease: State of the Art. Appl Radiol (2013) 0.77
Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure. Sci Rep (2015) 0.77
The expression and secretion of vimentin in the progression of non-alcoholic steatohepatitis. BMB Rep (2014) 0.77
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci (2015) 0.76
Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis. Dig Dis Sci (2015) 0.76
Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. Int J Endocrinol (2015) 0.76
Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice. Hepatology (2010) 0.76
Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. Sci Rep (2016) 0.75
Acute steatohepatitis, due to extreme metabolic dysregulation, as the first presentation of non-alcoholic fatty liver disease. Clin Pract (2013) 0.75
Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol (2016) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Cell death: critical control points. Cell (2004) 22.56
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell (2004) 3.49
Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology (2007) 2.82
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Apoptosis: a mechanism of acute and chronic liver injury. Gut (2005) 2.33
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology (2004) 2.18
Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab (2008) 2.12
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology (2006) 2.04
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis (2008) 2.04
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology (2008) 1.93
Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr (2005) 1.84
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology (2008) 1.71
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg (2005) 1.42
Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol (2008) 1.36
Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol (2007) 1.28
Mitochondrial functions during cell death, a complex (I-V) dilemma. Cell Death Differ (2003) 1.20
Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol (2003) 1.17
Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers (2006) 1.05
A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem (2008) 0.89
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Alcoholic liver disease. Hepatology (2010) 5.04
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology (2010) 4.83
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol (2008) 4.01
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int (2011) 2.85
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Hypoxemia during moderate sedation for gastrointestinal endoscopy: causes and associations. Digestion (2011) 1.67
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl (2008) 1.61
Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol (2004) 1.60
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med (2005) 1.43
Endoscopic clips for closing esophageal perforations: case report and pooled analysis. Gastrointest Endosc (2007) 1.43
Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol (2006) 1.41
A 35-year-old Asian man with jaundice and markedly high aminotransferase levels. Cleve Clin J Med (2009) 1.39
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol (2008) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis (2002) 1.27
Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol (2005) 1.25
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol (2006) 1.21
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci (2009) 1.19
Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol (2004) 1.17
Measuring protein synthesis using metabolic ²H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem (2011) 1.16
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem (2010) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders. J Pediatr (2007) 1.13
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol (2002) 1.12
Giant insulinoma: case report and review of the literature. J Clin Endocrinol Metab (2004) 1.11
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol (2002) 1.03
Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl (2012) 1.03
Gender differences in the regulation of amino acid metabolism. J Appl Physiol (1985) (2003) 1.03
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol (2013) 1.01
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int (2013) 1.00
Recognizing and treating cutaneous signs of liver disease. Cleve Clin J Med (2009) 0.99
Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol (2010) 0.99
Bispectral index monitoring of conscious sedation with the combination of meperidine and midazolam during endoscopy. Clin Gastroenterol Hepatol (2007) 0.98
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report. J Oral Maxillofac Surg (2007) 0.96
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2008) 0.94
Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci (2011) 0.94
Diagnosis of celiac disease in adults based on serology test results, without small-bowel biopsy. Clin Gastroenterol Hepatol (2013) 0.93
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation (2011) 0.92
Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. J Hematop (2009) 0.91
Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int (2009) 0.91
The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol (2012) 0.91
Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2009) 0.90
Spontaneous bacterial peritonitis: recent data on incidence and treatment. Cleve Clin J Med (2004) 0.90
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. N Engl J Med (2006) 0.89
Advances in therapy for hepatitis C infection. Microbes Infect (2002) 0.89
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.89
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol (2014) 0.89
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol (2012) 0.88
Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism (2008) 0.88
Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol (2008) 0.88
Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci (2002) 0.88
Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol (2012) 0.87
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve Clin J Med (2005) 0.86